No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
GPCR Structure Therapeutics
- 47.635
- +0.115+0.24%
Trading Jun 20 10:09 ET
2.65BMarket Cap-22737P/E (TTM)
47.780High46.443Low59.97KVolume46.910Open47.520Pre Close2.82MTurnover0.16%Turnover RatioLossP/E (Static)55.69MShares75.01752wk High6.17P/B1.83BFloat Cap25.57052wk Low--Dividend TTM38.40MShs Float75.017Historical High--Div YieldTTM2.81%Amplitude20.800Historical Low46.976Avg Price1Lot Size
Intraday
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | Cantor Fitzgerald Reiterates Overweight on Structure Therapeutics, Maintains $65 Price Target
Could Structure Therapeutics Become the Next Novo Nordisk?
USA faces the most severe drug shortage in a decade, with low stock price drugs and weight loss drugs becoming "disaster zones".
Last year, the USA experienced the most serious drug shortage crisis in a decade.
JPMorgan to Wager on Weight-Loss Craze With $500 Million Fund
JPMorgan Chase & Co.’s asset-management arm raised more than $500 million for a biotech venture-capital fund that will bet on the hottest corner of health care: weight-loss drugs
GLP-1 Obesity Drug Coverage Dropped by Blue Cross Michigan: Report
Structure Therapeutics (GPCR) Rallying on Obesity Drug Data
Comments
It seems that they will be going for acquisition of easy to manufacture weight loss pills $Structure Therapeutics(GPCR.US$
USA faces the most severe drug shortage in a decade, with low stock price drugs and weight loss drugs becoming "disaster zones".
News offering dropped🤢 ❗️❗️❗️**FOR IMMEDIATE RELEASE** Globe wire newsletter June 3,2024 2:57 pm est
Therapeutics Inc, a leading biopharmaceutical company, public offer at $31.90 per share USD for the acquisition of 17 million shares. The offer is subject to closing on June 7, 2024. This move reflects the company's commitment to expanding its market presence and fostering financial growth. Investors and stakeholders are urged to capitalize on this lucrative opportunity. Therapeutics Inc antici...
Therapeutics Inc, a leading biopharmaceutical company, public offer at $31.90 per share USD for the acquisition of 17 million shares. The offer is subject to closing on June 7, 2024. This move reflects the company's commitment to expanding its market presence and fostering financial growth. Investors and stakeholders are urged to capitalize on this lucrative opportunity. Therapeutics Inc antici...
1
offering afterhours dobt get trapped
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
